Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,018 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose CS, Hellqvist Å, Roseti SL, Molfino NA, Llanos JP, Martin N, Bowen K, Griffiths JM, Parnes JR, Colice G. Corren J, et al. Among authors: cook b. Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24. doi: 10.1164/rccm.202210-2005OC. Am J Respir Crit Care Med. 2023. PMID: 37015033 Free PMC article. Clinical Trial.
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
Corren J, Brightling CE, Boulet LP, Porsbjerg C, Wechsler ME, Menzies-Gow A, Ambrose CS, Cook B, Martin N, Spahn J, Llanos JP. Corren J, et al. Among authors: cook b. Eur Respir J. 2023 Mar 30;61(3):2202202. doi: 10.1183/13993003.02202-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36997233 Free article. No abstract available.
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study.
Menzies-Gow A, Bourdin A, Chupp G, Israel E, Hellqvist Å, Hunter G, Roseti SL, Ambrose CS, Llanos JP, Cook B, Corren J, Colice G. Menzies-Gow A, et al. Among authors: cook b. Ann Allergy Asthma Immunol. 2023 Sep;131(3):343-348.e2. doi: 10.1016/j.anai.2023.05.028. Epub 2023 May 30. Ann Allergy Asthma Immunol. 2023. PMID: 37263380 Free article. Clinical Trial.
Reply to Lipworth and Chan.
Ambrose CS, Israel E, Bowen K, Llanos JP, Martin N, Cook B, Hellqvist Å, Korn S, Menzies-Gow A, Roseti SL, Molfino NA, Griffiths JM, Parnes JR. Ambrose CS, et al. Among authors: cook b. Am J Respir Crit Care Med. 2023 Jul 15;208(2):212-213. doi: 10.1164/rccm.202305-0843LE. Am J Respir Crit Care Med. 2023. PMID: 37279366 Free PMC article. No abstract available.
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).
Pavord ID, Hoyte FCL, Lindsley AW, Ambrose CS, Spahn JD, Roseti SL, Cook B, Griffiths JM, Hellqvist Å, Martin N, Llanos JP, Martin N, Colice G, Corren J. Pavord ID, et al. Among authors: cook b. Ann Allergy Asthma Immunol. 2023 Nov;131(5):587-597.e3. doi: 10.1016/j.anai.2023.08.015. Epub 2023 Aug 23. Ann Allergy Asthma Immunol. 2023. PMID: 37619779 Free article. Clinical Trial.
Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma.
Lugogo NL, Kreindler JL, Martin UJ, Cook B, Hirsch I, Trudo FJ. Lugogo NL, et al. Among authors: cook b. Ann Allergy Asthma Immunol. 2020 Aug;125(2):171-176. doi: 10.1016/j.anai.2020.04.011. Epub 2020 Apr 22. Ann Allergy Asthma Immunol. 2020. PMID: 32334141 Free article. Clinical Trial.
1,018 results